Sorafenib is a multitargeted tyrosine kinase inhibitor used in advanced stage renal cell carcinoma (RCC). A small prospective trial (30 patients with stage II or higher RCC) in the Journal of Clinical Oncology took a look at the safety and feasiblity of sorafenib in the preoperative setting.
Authors found that administering sorafenib prior to nephrectomy forRCC can reduce the size of the primary tumor without adding to the risk of surgery.
“We found that primary kidney tumors responded to this therapy, shrinking up to 40% prior to surgery,” said principal investigator Kimryn Rathmell, MD, PhD, Assistant Professor of Medicine. “What this means for kidney cancer patients is that their surgery may be less extensive.”
Again, this is a small study with limitations. Although it does look promising.. is it cost effective?
1 comments:
Sounds great.
Sunitinib, its sister drug and sorafenib have been associated with anti VEGF affects on the kidneys and "pre eclampsia" like syndrome and now more cases of AIN as well.
Something to watch out for once this drug gets more into the main stream.
Post a Comment